Alvotech

Alvotech is not a fund or investment vehicle — it is a Nasdaq-listed operating pharmaceutical company. R&D allocation and commercialization strategy are driven by the executive team led by CEO Mark Levick and Chairman Róbert Wessman. Capital allocation decisions — including its SPAC merger and subsequent equity raises — are executed under Board supervision. The firm does not operate an external LP capital pool.

Alvotech and Teva entered a strategic partnership in August 2020 granting Teva exclusive US commercialization rights to AVT02, Alvotech's Humira biosimilar. The deal structure shares profit rather than relying on a traditional royalty model. Teva invested capital into Alvotech and assumed responsibility for US sales, marketing, and reimbursement access, while Alvotech handles development, manufacturing, and regulatory filing.

Alvotech is a publicly listed specialty pharmaceutical company — not a family office, venture firm, or fund — that concentrates exclusively on biosimilars. Its Nasdaq listing and SPAC merger route make it an operational entity rather than an investment platform, though founder Róbert Wessman retains significant governance influence through a multi-tiered Nordic holding structure.

Publicly disclosed programs include AVT02 (adalimumab, referencing Humira), AVT04 (ustekinumab, referencing Stelara), AVT05 (golimumab, referencing Simponi), AVT06 (aflibercept, referencing Eylea), AVT03 (denosumab, referencing Prolia/Xgeva), and AVT23 (omalizumab, referencing Xolair). Several assets are in Phase III or under regulatory review across US, EU, and other major markets (per the firm).

Primary manufacturing is conducted at Alvotech's dedicated facility near Reykjavík Science Park in Iceland, which houses cell culture, purification, and fill-finish lines within a single campus. In 2023 the company announced a secondary fill-finish site in Hannover, Germany to support expanded capacity and EU distribution redundancy, with expected operational readiness in 2025 (per the firm).

The SPAC structure — a merger with Oaktree Capital Management-backed OACB in June 2022 — provided Alvotech a faster route to public markets and unlocked committed PIPE funding to support the build-out of its manufacturing capacity. The transaction gave the firm an enterprise value of roughly $2.25 billion at closing and listed shares on both Nasdaq Iceland and the Nasdaq Global Select Market in New York.

Wessman founded generic pharmaceutical company Alvogen in 2009 and grew it into a global operation before selling a controlling stake to CVC Capital Partners in a deal that valued the company at approximately $2.7 billion. Prior to Alvogen, he led Actavis Group — not the US firm — from 1999 until its 2007 sale to Watson Pharmaceuticals. His entire career has been focused on building complex generic and biosimilar manufacturing platforms from Iceland outward.